



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Marleen Renard**

Organisation/Company: University Hospitals Leuven

Country: Belgium

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
01/2014-01/2019	Grünenthal	Tapentadol	oncology pain in pediatric patients
01/2014-01/2015	Sanofi	plerixaflor	mobilization autologous stemcells in pediatric patients with solid tumour
01/2015-(current)	MSD	posaconazole	fungal infection in immunocompromised pediatric patients with neutropenia

Classified as public by the European Medicines Agency

2

01/2017-(current)	Jazz pharmaceuticals	defibrotide	VOD in pediatric stemcell transplant patients
01/2018-(current)	Novartis	ruxolitinib	GvHD in pediatric transplant patients

2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2011-01/2016	Roche	avastin	high grade glioma
01/2015-01/2019	bayer	rivaroxaban	thrombosis
01/2015-01/2019	Amgen	blinatumumab	relapsed ALL
01/2017-01/2019	Abbvie	ABT-414	Brain tumour
01/2015-01/2019	Amgen	romiplostim	ITP
01/2016-(current)	Johnson and Johnson	ibrutinib	Lymphoma
01/2020-(current)	Novartis	Dabrafenib/trametinib	high/low grade glioma
01/2018-(current)	MSD	Avelumab	relapsed solid tumors/lymphoma
01/2019-(current)	Bristole Meyers	Apixaban	ALL/trombosis

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

No interest declared

2.11 CAT member or alternate

No interest declared

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	marleen renard
Date:	2020-12-18

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template